0224 Vividion
BioCentury & Getty Images


$135M series C buys Vividion flexibility to explore broad pipeline 

Crossover investors, deals with Roche, BMS provide runway

A new venture round back by deep-pocketed crossover investors and a pair of pharma deals give Vividion runway to explore a platform based on technology from Ben Cravatt’s lab.

Feb 25, 2021 | 3:23 AM GMT

After its $135 million series C raise Wednesday, Vividion has everything in

Read the full 689 word article

How to gain access

Continue reading with a
two-week free trial.